Correvio announces Brinavess selected as potentially eligible for priority review in China
Correvio Pharma announced that Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), was selected by the CFDA Center for Drug Evaluation as potentially eligible for priority review. August 14, 2018